Did the new directors understand their market release on their very first day???

I can't make this out, this is from the quarterly.

Since October 2020 the Company continued to work with Medleaf to revise the commercial arrangements both around the product release and sharing of additional costs required to comply with the transitioning New Zealand government medical cannabis framework.

I can't find that there were any transitions in the New Zealand government medicinal cannabis framework that resulted in any additional costs.

What additional costs were there to share? Can one of the new directors clarify?